2020 American Transplant Congress Archives - Page 24 of 223

ATC Virtual Congress
Live Broadcast Dates: May 30 - June 1, 2020
OnDemand Access: May 30, 2020 - June 4, 2021

Originally scheduled to take place in Philadelphia, this became a Virtual Congress due to COVID-19. For more information, visit The Official ATC Congress site.

Belatacept Every Two Month Maintenance Dosing in Kidney Transplantation: A Randomized, Non-Inferiority Trial

I. R. Badell, R. Parsons, S. Mead, S. Thomas, G. Karadkhele, S. Pastan, C. Larsen
Belatacept in Kidney Transplant Recipients with Previous Non-Renal Solid Organ Transplants

O. Cristea, C. Larsen, I. Badell
Belatacept Monthly Therapy: Transplant Recipients’ Experience

S. N. Little¹, É. N. Arsenault Knudsen², D. A. Mandelbrot¹
Belatacept Provides Superior Inhibition of Donor Specific Antibody Formation in Kidney Transplant Recipients with Acute Rejection

O. Cristea, C. Larsen, I. Badell
Belatacept Removal by Plasmapheresis: Kinetics, Dose Adjustments and Clinical Recommendations

S. Tremblay¹, N. Wilson¹, B. Miyagawa², H. Kuzaro¹, A. R. Shields³, R. R. Alloway¹, A. Govil¹, J. Kremer⁴, E. Woodle¹, T. Mizuno², A. A. Vinks²
Belatacept Suppresses the B-Cell Alloresponse in the Lower Range of Therapeutic Trough Concentrations

C. Ashokkumar¹, R. Townsend², M. Roberts², T. Lehman², B. Gavin², B. Spishock¹, R. Sindhi¹
Belatacept versus Tacrolimus Combined with Antithymocyte Globulin in Kidney Transplantation

J. Goldman¹, A. Mitrokhin², B. Trivedi¹, V. Vidyasagar¹, N. Vadivel¹, N. Goes³, M. Hart¹
Belatacept-Based Regimens: Induction and Recipient Gender Influence Outcomes

N. Wilson¹, A. R. Shields², A. Wiseman³, A. L. Christianson¹, S. Tremblay¹, D. Kaufman⁴, J. P. Leone⁵, A. J. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
Belatacept-Based, Calcineurin Inhibitor and Corticosteroid Free Immunosuppression: Differential Outcomes Based on Recipient Age

N. Wilson¹, A. R. Shields², D. Kaufman³, A. Wiseman⁴, A. L. Christianson¹, S. Tremblay¹, J. P. Leone⁵, A. J. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
Benefits of Normothermia Regional Perfusion (NRP), Hypothermic Machine Perfusion (HMP) and Short Cold Ischemia Time (CIT) for Kidney Transplants with Controlled Donation after Circulatory Death (cDCD)

E. Savoye¹, C. Legeai¹, J. Branchereau², S. Gay³, S. Drouin⁴, F. Gaudez⁵, B. Veber⁶, J. Venhard⁷, G. Cheisson⁸, T. Kerforne⁹, O. Bastien¹, C. Antoine¹